Search

Displaying results 21 - 30 of 108 in total
  1. Indication

    Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction

    go.drugbank.com/conditions/DBCOND0144319
    Drugs: Pembrolizumab
  2. Indication

    Stage 2 Non-Small Cell Lung Cancer (NSCLC)

    go.drugbank.com/conditions/DBCOND0173420
    Drugs: Pembrolizumab
  3. Indication

    Unresectable High Tumor Mutation Burden Solid Tumors

    go.drugbank.com/conditions/DBCOND0144325
    Drugs: Pembrolizumab
  4. Indication

    Unresectable, locally advanced HER2 negative Gastroesophageal Junction Adenocarcinoma

    go.drugbank.com/conditions/DBCOND0171120
    Drugs: Pembrolizumab
  5. Indication

    Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach

    go.drugbank.com/conditions/DBCOND0144311
    Drugs: Pembrolizumab
  6. Indication

    Unresectable, locally recurrent Triple Negative Breast Cancer

    go.drugbank.com/conditions/DBCOND0144330
    Drugs: Pembrolizumab
  7. Indication

    Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    go.drugbank.com/conditions/DBCOND0144293
    Drugs: Pembrolizumab
  8. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...

  9. Indication

    FIGO 2014 Stage III-IVA Cervical Cancer

    go.drugbank.com/conditions/DBCOND0163323
    Drugs: Pembrolizumab
  10. Indication

    Stage IB Non-small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0028480
    Drugs: Pembrolizumab